A Two Part Seamless, Multi-Center Randomized, Placebo-Controlled, Double-Blind Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of RO7034067 in Type 2 and 3 Spinal Muscular Atrophy Patients
Phase of Trial: Phase II
Latest Information Update: 18 Apr 2018
At a glance
- Drugs RG 7916 (Primary)
- Indications Spinal muscular atrophy
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms SUNFISH
- Sponsors Chugai Pharmaceutical; Roche
- 16 Apr 2018 According to the Genentech media release, updated pharmacodynamic and safety data from Part 1 of this trial will be presented at the 70th American Academy of Neurology (AAN) Annual Meeting 2018.
- 27 Jan 2018 According to a PTC Therapeutics media release, updated pharmacodynamic and safety data from Part 1 of this trial were presented at the International Scientific Congress on Spinal Muscular Atrophy.
- 26 Jan 2018 Planned End Date changed from 5 May 2020 to 16 Jul 2020.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History